Page last updated: 2024-10-20

taurine and Shock, Septic

taurine has been researched along with Shock, Septic in 5 studies

Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.

Research Excerpts

ExcerptRelevanceReference
"Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes."2.40Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19902 (40.00)18.7374
1990's2 (40.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vermeulen, MA1
van Stijn, MF1
Visser, M1
Lemmens, SM1
Houdijk, AP1
van Leeuwen, PA1
Oudemans-van Straaten, HM1
Janssen, HF1
Lombardini, JB1
Lust, RM1
Wang, WY1
Wheeler, MD1
Ikejema, K1
Enomoto, N1
Stacklewitz, RF1
Seabra, V1
Zhong, Z1
Yin, M1
Schemmer, P1
Rose, ML1
Rusyn, I1
Bradford, B1
Thurman, RG1
McCartney, AC1
Browne, MK1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481]Phase 213 participants (Actual)Interventional2012-03-31Terminated (stopped due to Some of the researchers finished their participation in the study.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.3908
Placebo0.2035

Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.0819
Placebo0.1668

Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

Interventionlog (percent change) (Mean)
Glycine-0.00007
Placebo0.1739

Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Cough questionnaire scoreAppetite questionnaire scoreEnergy questionnaire scoreBody weightHeightHeart rateRespiratory rateTemperature
Glycine81.189.184.6101.6100.5103.594.8100.0
Placebo89.1132.1111.5103.6100.598.1109.0100.1

Changes in FEV1, FEF25, and FEFmax

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced expiratory volume at first second (FEV1)Forced expiratory flow at 25%FVC (FEF25)Maximal forced expiratory flow (FEFmax, PEFR)
Glycine109.7133.9115.3
Placebo91.483.391.2

Changes in Other Spirometric Variables

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Forced vital capacity (FVC)Forced expiratory flow at 75%FVC (FEF75)
Glycine104.1111.8
Placebo100.6108.9

Changes in Pulse Oximetry, FEV1/FVC, and FEF50.

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Peripheral oxygen saturation (SpO2)FEV1/FVCForced expiratory flow at 50%FVC (FEF50)
Glycine105.2105.2115.5
Placebo98.994.993.1

Changes in Score for Sputum Production, Dyspnea and Global Symptoms

"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks

,
InterventionPercentage of baseline (Mean)
Sputum questionnaire scoreDyspnea questionnaire scoreTotal questionnaire score
Glycine82.075.677.7
Placebo102.6103.898.7

Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-4IL-6IL-7IL-8IL-12IL-13G-CSFIFN-gammaMCP-1MIP-1beta
Glycine-0.4361-0.16350.29640.00850.0356-0.14660.3203-0.0561-0.07760.3272-0.08360.0330
Placebo-0.2906-0.03520.14700.22550.0819-0.23640.26030.19530.22720.36390.0472-0.0608

Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)

To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks

,
Interventionlog (percent change) (Mean)
MyeloperoxidaseIL-1IL-2IL-4IL-5IL-7IL-8IL-10IL-12IL-13IL-17IFN-gammaMCP-1MIP-1betaTNF-alphaGM-CSF
Glycine0.1294-0.09180.0233-0.01610.24980.0611-0.08240.05490.16750.16300.06800.02480.0042-0.03030.0412-0.0538
Placebo0.0669-0.0102-0.02740.05220.13040.13870.05420.00740.06770.09530.11400.06490.26080.09770.1568-0.0822

Reviews

1 review available for taurine and Shock, Septic

ArticleYear
Glycine: a new anti-inflammatory immunonutrient.
    Cellular and molecular life sciences : CMLS, 1999, Nov-30, Volume: 56, Issue:9-10

    Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori

1999

Trials

1 trial available for taurine and Shock, Septic

ArticleYear
Clinical studies on administration of taurolin in severe sepsis: a preliminary study.
    Progress in clinical and biological research, 1988, Volume: 272

    Topics: Aged; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Endotoxins; Female; Hum

1988

Other Studies

3 other studies available for taurine and Shock, Septic

ArticleYear
Taurine Concentrations Decrease in Critically Ill Patients With Shock Given Enteral Nutrition.
    JPEN. Journal of parenteral and enteral nutrition, 2016, Volume: 40, Issue:2

    Topics: Amino Acids; APACHE; Critical Illness; Enteral Nutrition; Female; Hospital Mortality; Humans; Intens

2016
Cardiac taurine levels during endotoxemia.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1983, Volume: 172, Issue:4

    Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Myocardium; Shock, Septic; Taurine

1983
[Intestinal endotoxin translocation in endotoxemic rats].
    Sheng li ke xue jin zhan [Progress in physiology], 1995, Volume: 26, Issue:1

    Topics: Animals; Endothelins; Endotoxins; Intestinal Mucosa; Mice; Rats; Shock, Septic; Taurine; Toxemia

1995